

February 24, 2026

To,  
National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400051  
(**SYMBOL: THYROCARE**)

BSE Limited  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400001  
(**SCRIP CODE 539871**)

**Sub: Disclosure under Regulation 30 – Additional Capital infusion in Thyrocare Laboratories (Tanzania) Limited**

**Dear Sir/Madam,**

This is in reference to our earlier communications dated September 19, 2023, December 03, 2024, March 03, 2025 and June 03, 2025, regarding the establishment and investment in Thyrocare Laboratories (Tanzania) Limited (“Thyrocare Tanzania”). Thyrocare Tanzania operates in the diagnostic and healthcare services sector and is a joint venture between Thyrocare Technologies Limited (“Thyrocare India” or “the Company”) and the Kastipharm Group, comprising Kastipharm Limited, Mr. Anwar Alnoor Kachra and Mr. Joseph Philemon Mgaya.

We are pleased to inform you that on February 24, 2026, the Company has made an additional investment of USD 4,75,000 (equivalent to INR 4,32,91,500.00/-) in Thyrocare Tanzania, subsidiary of the Company by subscribing to Compulsorily Convertible Irredeemable Preference Shares (CCPS).

The details, as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), read with SEBI Master Circular dated January 30, 2026 (Reference No. [SEBI/HO/49/14/14\(7\)2025-CFD-POD2/I/3762/2026](#)), are provided in the statement attached as “**Annexure A**”.

We request you to kindly take this on record.

Yours Faithfully,

For **Thyrocare Technologies Limited**



**Brijesh Kumar**  
Company Secretary and Compliance Officer  
ICSI Mem No. A36070  
Place: Navi Mumbai

**Annexure A**

Sr	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	<p><b>Name:</b> Thyrocare Laboratories (Tanzania) Limited (“Thyrocare Tanzania”)</p> <p>Brief details of Thyrocare Tanzania:</p> <ul style="list-style-type: none"> <li>• <b>Turnover:</b> INR 1.84 Crores for the year ended December 31, 2025.</li> <li>• <b>Net-worth:</b> INR (0.32) Crores as on December 31, 2025.</li> <li>• <b>Authorised Capital:</b> 10,00,000 ordinary shares of face value of 10,000 Tanzania Shillings each.</li> </ul>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm's length”	<p>Yes, the investment by subscribing of Compulsorily Convertible Irredeemable Preference Shares (“CCPS”) of Thyrocare Tanzania is a related party transaction.</p> <p>Save and except as stated above, the promoters/promoter group are not otherwise interested.</p> <p>The transaction has been carried out at arm's length.</p>
3.	Industry to which the entity being acquired Belongs	Healthcare Services
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity	<p>The capital infusion in Thyrocare Tanzania has been made to facilitate its business operations and working capital requirements.</p> <p>Thyrocare Tanzania's business is similar to the Company's main line of business viz. diagnostic and healthcare services.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition	<p>Not Applicable.</p> <p>Necessary filings and/or reporting will be made as per applicable laws.</p>

6.	Indicative time period for completion of the Acquisition	<p>As per the approval of the Company's Board, a total investment of up to INR. 15 Crores can be made by the Company in one or more tranches, in Thyrocare Tanzania from time to time, based on business requirements.</p> <p>The total investment made by the Company till date (including this tranche of USD 4,75,000) amounts to USD 11,50,020 (equivalent to INR 10,01,62,414/-).</p> <p>The remaining capital infusion will be made by the Company in one or more tranches, depending on Thyrocare Tanzania's business requirements.</p>									
7.	Consideration - whether cash consideration or share swap or any other form and details of the Same	Cash Consideration									
8.	Cost of acquisition and/or the price at which the shares are acquired	Total investment till date: USD 11,50,020 (equivalent to INR 10,01,62,414/-), including the current investment of USD 4,75,000									
9.	Percentage of shareholding / control acquired and / or number of shares acquired	<p>The percentage of shareholding of the Company in Thyrocare Tanzania is as follows:</p> <table border="1" data-bbox="842 1043 1497 1234"> <thead> <tr> <th>Securities</th> <th>Existing % of Holding</th> <th>Post-Allotment % of Holding</th> </tr> </thead> <tbody> <tr> <td>Equity Shares</td> <td>57.25%</td> <td>57.25%</td> </tr> <tr> <td>CCPS</td> <td>100.00%</td> <td>100.00%</td> </tr> </tbody> </table>	Securities	Existing % of Holding	Post-Allotment % of Holding	Equity Shares	57.25%	57.25%	CCPS	100.00%	100.00%
Securities	Existing % of Holding	Post-Allotment % of Holding									
Equity Shares	57.25%	57.25%									
CCPS	100.00%	100.00%									
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Thyrocare Tanzania is a company incorporated in the Republic of Tanzania, with Registration Number 168657943, dated September 19, 2023, and operates in the diagnostic and healthcare services sector.</p> <p>The turnover for the year ended December 31, 2025, is provided in Point 1 of this table. As Thyrocare Tanzania is a newly incorporated entity, the turnover history for the last three years is not applicable.</p>									